Kornimate/medical-research-clean huggingface dataset:
patient registry for patients with chronic subdural hematoma

Conditions: Hematoma; Subdural Hematoma; Chronic

Summary: all admitted patients diagnosed with unilateral or bilateral chronic subdural hematoma are included into this registry after consent. clinical condition, radiological details, therapy (intervention/medication treatment/conservative) and outcome are documented. patient follow-up is documented over at least 24 month with focus on neurological condition (nihss), cognitive impairment (moca) and quality of life (sf-12 ver. 2).

chronic subdural hematoma (csdh) is a frequent disease in- predominantly - elderly patients often caused by minor trauma to the bridging veins eventually leading to a collection of old blood in the subdural space over time. besides age of the patients a number of further risk factors are assumed to favor pathogenesis. depending on size and location of blood collections diverse neurological symptoms can be seen. therapy approaches are heterogeneous ranging from conservative treatment with or without medication to surgical treatment. there also is lacking knowledge regarding neurocognitive impairment and effects on quality of life in patients under different therapy regimes. the prospective patient registry will enclose all patients admitted to the investigator's department diagnosed with csdh either by mri or ct scan after informed consent. medical history, regular medication, social status, radiological findings and neurological examination using nihss will be performed at time of inclusion, discharge and follow-up. additionally, neurocognitive testing and documentation of quality of life using moca test and sf-12 will be conducted at different timepoints. moreover a detailed documentation of therapy strategies is implemented in the study protocol. with this registry the study group expects to obtain significant data leading to a more standardized and optimized therapy regime and furthermore widening understanding on so far rarely known impact of csdh on neurocognition and quality of life.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral chronic subdural hematoma * patient consent exclusion criteria: * acute subdural hematoma * no patient consent * subdural hygroma

Keywords: hemorrhage subdural chronic subdural hematoma chronic
male sexual health questionnaire (mshq) - sexual function study

Conditions: Prostatic Hyperplasia

Summary: primary: to assess improvement in ejaculation from baseline to the end of treatment (week 12 or premature withdrawal) with alfuzosin 10mg od, using mshq score. secondary: * to evaluate sexual function improvement * to evaluate luts (lower uninary tract symptoms) improvement * to evaluate the association between luts severity and sexual function. * to assess the safety and the tolerability of alfuzosin 10mg od.


Eligibility criteria:
inclusion criteria: * patients suffering from moderate to severe lower urinary tract symptoms (luts), suggestive of symptomatic benign prostatic hyperplasia (bph) diagnosed by the investigator * patients with an i-pss total score ≥ 8 * patients sexually active as defined by at least one of the following activities in the last 4 weeks: intercourse, caressing, foreplay, masturbation exclusion criteria: * patients with a known history of hepatic or severe renal insufficiency, unstable angina pectoris * patients who had a previous prostate surgery * patients who had a prostate biopsy or minimally invasive procedure within 6 months prior to inclusion * patients with a prostate surgery or minimally invasive procedure during the whole study period * patients with an active urinary tract infection or prostatitis * patients with a neuropathic bladder defined as a spinal injury consequence or related to a neurological disorder or a known residual volume ≥ 350 ml * patients with a diagnosed prostate cancer * patients having received 5a-reductase inhibitors or luts related-phytotherapy within 6 months prior to inclusion, or a1-blockers within 30 days prior to inclusion * patients receiving any treatment for erectile dysfunction (i.e. phosphodiesterase-5 inhibitors) at inclusion * patients with a history of postural hypotension or syncope * patients with a known hypersensitivity to alfuzosin the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
efficacy of transversalis fascia plane block versus wound infiltration in varicoselectomy surgery

Conditions: Analgesia; Transversalis Fascia Plane Block; Wound Infiltration; Varicoselectomy

Summary: before surgery, patients will be divided into 2 groups as transversalis fascia plane block will be applied and skin infiltration will be applied. post-operative analgesic procedures will be applied to patients receiving general anesthesia. postoperative analgesic consumption and pain scores of the patients will be evaluated.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 who will undergo varicocele operation * asa i-ii exclusion criteria: * patients with allergic reaction to anesthesia and analgesia drugs to be used * patients who did not want to voluntarily participate in the study * severe systemic disease (kidney, liver, pulmonary, endocrine) * substance abuse history * chronic pain history * psychiatric problems and communication difficulties * history of hematological problem * patients with severe hemodynamic instability due to infection, heavy bleeding
evaluation of metabolic activity of liver metastases by fdg-pet scanning

Conditions: Colorectal Neoplasms

Summary: the purpose of this study is to evaluate the effect of primary tumor resection on the metabolic activity of metastases in patients with a colorectal primary tumor and synchronous liver metastases by positron emission tomography (pet) with 2-deoxy-2-fluoro\[18f\]-d-glucose (fdg-pet) scanning.

the goal of this study is to evaluate the activity of liver metastases before and after resection of the primary tumor. non-invasive assessment of tumor metabolism is possible in vivo by means of positron emission tomography (pet)-scanning. therefore, fdg-pet scan offers a suitable approach to determine the influence of removal of a primary colorectal tumor on metabolic activity of the liver metastases. the fdg uptake in the liver metastases is quantified by calculating standardised uptake values (suvs).

Eligibility criteria:
inclusion criteria: * colorectal cancer and synchronous liver metastases exclusion criteria: * pregnancy

Keywords: colorectal cancer liver metastases metabolic activity
preoperative patient warming for prevention of perioperative hypothermia in major abdominal surgery

Conditions: Preoperative Warming; Prewarming; Perioperative Hypothermia; General Anaesthesia; Epidural Anaesthesia; Temperature Monitoring

Summary: the study should evaluate how long patients undergoing major abdominal surgery under combined general/epidural anaesthesia have to be actively warmed preoperatively to prevent perioperative hypothermia and postoperative shivering. 99 patients will receive forced-air skin-surface warming for different duration. body temperature will be measured at the tympanic membrane. the investigators hypothesize that active warming before starting the epidural anaesthesia will decrease the incidence of perioperative hypothermia.

the aim of our study is to evaluate the performance of different durations of active preoperative skin-surface warming (prewarming) to prevent perioperative hypothermia in patients undergoing major abdominal surgery under combined general/epidural anaesthesia. the investigators plan to enroll 99 patients in 3 groups. body temperature will be measured at the tympanic membrane. the investigators hypothesize that active warming before starting the epidural anaesthesia will decrease the incidence of perioperative hypothermia.

Eligibility criteria:
inclusion criteria: * age over 18 years * planned duration of surgery \> 2 hours * planned for elective major abdominal surgery under combined epidural/general anaesthesia * written informed consent * american society of anesthesiologists status 1-3 exclusion criteria: * duration of surgery \< 90 min * withdrawal of consent * emergency surgery

Keywords: perioperative hypothermia prewarming preoperative warming general anaesthesia epidural anaesthesia temperature measurement
comparison of different dose of post-transplantation cyclophosphamide as graft versus host disease prophylaxis

Conditions: GVHD

Summary: post-transplantation cyclophosphamide (ptcy) is considered as major graft versus host disease (gvhd) prophylaxis. in our previous study, the investigators demonstrated that the standard dose ptcy of 50mg/kg with tacrolimus and post-engrafted low-dose anti-thymoglobulin (atg) achieved low incidence of acute gvhd. more recently, it has been shown that reduced dose of ptcy of 40mg/kg is considered with similar efficacy as gvhd prophylaxis, in this study, a multi-center randomized comparison is planned to evaluate the clinical outcome of gvhd prophylaxis of ptcy 40 versus 50.

post-transplantation cyclophosphamide (ptcy) is considered as major graft versus host disease (gvhd) prophylaxis. in our previous study, the investigators demonstrated that the standard dose ptcy of 50mg/kg with tacrolimus and post-engrafted low-dose anti-thymoglobulin (atg) achieved low incidence of acute gvhd. in the clinical setting, reduced dose of ptcy (40mg/kg) was used for patients over 60 or with high hct-ci and the overall incidence of acute gvhd was similar to ptcy 50mg/kg but chronic gvhd was slightly increased. to confirmed our observation, in this study, a prospective multiple-center randomized comparison is planned to evaluate the clinical outcomes of reduced dose of ptcy (40mg/kg) versus 50mg/kg as gvhd prophylaxis.

Eligibility criteria:
inclusion criteria: * patients with hematological malignancies * patients undergo allogeneic stem cell transplantation from haplo-identical donors * patents with informed consent provided exclusion criteria: * patients with active infection ()bacteria, fungal or viral) * patients with liver, renal and cardiac dysfunction not suitable for undergoing allogeneic stem cell transplantation.

Keywords: graft versus host disease (gvhd) post-transplantation cyclophosphamide (ptcy) allogeneic stem cell transplantation haplo-identical donor
high intensity laser therapy in the treatment of hemiplegic shoulder pain

Conditions: Shoulder Pain; Hemiplegia; Arthralgia; Joint Diseases; Musculoskeletal Diseases

Summary: high intensity laser therapy (hilt) has been considered as a treatment option for shoulder pain. in randomized controlled studies with high-intensity laser therapy (hilt), there are publications showing its effectiveness in conditions such as shoulder pathologies such as subacromial impigment syndrome and adhesive capsulitis. however, there are few studies in the literature that focus on the effectiveness of hilt, especially in hemiplegic shoulder pain. in this study, we intended to investigate the effectiveness of hilt on pain, disability, function and quality of life in patients with hsp accompanied by ptrct.

the study was designed as prospective, randomized, controlled trial. patients with hsp accompanied by ptrct (n=40) were randomly assigned to hilt and control groups. group 1 (hilt group, n=20) received 3 sessions of hilt per week for 3 weeks in addition to the exercise program which performed 5 sessions per week for 3 weeks. group 2 (control group, n=20) received an exercise program for hsp of 5 sessions per week for 3 weeks. participants were evaluated with visual analog scale (vas), passive range of motion (rom), shoulder pain and disability index (spadi), nottingham health profile (nhp), functional independence measure (fim) and ultrasonographic ptrct size,fugl meyer assessment, brunnstrom stages, modified ashworth scale (mas) nottingham health profile (nhp).

Eligibility criteria:
inclusion criteria: * patients with hsp aged 50-85 years with hemiplegia duration\> 2 months, suffered a stroke resulting in unilateral hemiplegia for the first time exclusion criteria: * cases who had inflammatory rheumatic disease, cervical radiculopathy, diabetes mellitus, thyroid disease, coronary heart disease, cardiac pace-maker, neurological disease, shoulder surgery, and shoulder injection in the last 3 months

Keywords: hemiplehic shoulder pain rotator cuff tear high intensity laser therapy exercise ultrasound
gastric motor function measurement in dyspepsia and normal subjects

Conditions: Dyspepsia

Summary: this study is being done to measure the functions of the stomach after eating a meal and to develop a new method that will simultaneously measure both gastric emptying and the relaxation of the stomach after a meal using nuclear medicine testing. this would make the testing more convenient for patients and will also offer better understanding of these two gastric functions.


Eligibility criteria:
inclusion criteria: dyspeptic subjects: * recurrent episodes of upper abdominal pain or discomfort including early satiety, fullness, bloating, or nausea for at least 3 months in the prior year. * a baseline impaired satiety test (maximum tolerated volume 25% of normal or 1000cc). * no evidence on esophagogastroduodenoscopy of erosions, peptic ulcer, pyloric obstruction, esophagitis or malignancy in the prior 3 years. all subjects: * no history suggestive of small bowel obstruction. exclusion criteria * no structural or metabolic diseases/conditions that affect the gastrointestinal system. * unable to stop medications 48 hours prior to the study that: * alter gi transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, ssri and newer antidepressants. * analgesic drugs including opiates, nsaid, cox 2 inhibitors * systemic antifungal drugs * carbamazepine, glucocorticoids, phenobarbital, phenytoin, rifampin, but also grapefruit juice. * benzodiazepines note: low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection and birth control pills or depot injections are permissible. * female subjects who are pregnant or breast feeding. * significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. * subjects who have participated in another clinical study within the past 30 days. * previous gastric or intestinal surgery (except appendectomy , cholecystectomy or hysterectomy).
neuroimaging studies of the treatment of bipolar depression with citalopram

Conditions: Bipolar Depression

Summary: regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-fluorodeoxyglucose positron emission tomography imaging, will be characterized (fdg pet).

regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-fluorodeoxyglucose positron emission tomography imaging, will be characterized (fdg pet). the following hypothesis will be tested: antidepressant response or remission in depressed bpd patients will be associated with changes in cortical (prefrontal, parietal, premotor) and paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and anterior insula) regions, consistent with sri antidepressant response in unipolar depressed patients.

Eligibility criteria:
inclusion criteria: * current age 18-64 years; dsm-iv diagnosis of bpd, type-i, or type-ii; enrolled in the citalopram study at tufts medical center exclusion criteria: * current pregnancy, or inability to utilize contraception, the presence of any metallic implants, history of claustrophobia
stunning in acute myocardial infarction - bas

Conditions: Myocardial Infarct

Summary: the objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (acei), and sodium/glucose cotransporter 2 (sglt2) inhibitors on echocardiographic parameters and biomarkers in subjects with st-elevation myocardial infarction (stemi)

left ventricular (lv) remodeling after st-elevation myocardial infarction (stemi) is associated with poor outcomes, but the mechanisms underlying adverse lv remodeling are poorly understood. it is also poorly understood how current guideline-recommended treatments affect early lv remodeling. this low interventional clinical trial will compare the effects of early versus late initiation of the three pharmacotherapies on early lv remodeling and cardiometabolic profiles. trial objective: the objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (acei), and sodium/glucose cotransporter 2 (sglt2) inhibitors on echocardiographic parameters and biomarkers in subjects with st-elevation myocardial infarction (stemi). primary endpoint: global longitudinal strain (gls, %) at day 7±24 hours after pci, adjusted for baseline (day 0) gls. trial design: this prospective, 2x2x2 factorial, randomized, controlled, open-label, low intervention clinical trial will enroll subjects with stemi who undergo primary percutaneous coronary intervention (pci) within 6 hours of symptom onset. trial population: patients over the age of 18 with stemi who undergo primary pci

Eligibility criteria:
inclusion criteria: 1. patients with stemi who undergo primary pci within 6 hours of symptom onset (excluding prodromal symptoms) 2. informed consent exclusion criteria: 1. killip class ≥ 3 2. chronic kidney disease with gfr \< 25 ml/min/1.73 m2 3. pre-existing non-reversible cardiac dysfunction or heart failure 4. current treatment with any beta blocker, raas inhibitor or sglt2 inhibitor 5. absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician 6. life expectancy less than one year 7. pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception

Keywords: st infarction pci bisoprolol ramipril dapagliflozin global longitudinal strain (gls, %)
mother scented simulated hand for mechanically ventilated preterm neonates during invasive procedures?

Conditions: Pain; Distress, Emotional

Summary: this study aimed to determine the effect of mother-scented simulated hand (mssh) on promoting comfort among mechanically ventilated preterm neonates during invasive procedures. research hypotheses * preterm neonates who receive msshh exhibit higher levels of comfort during invasive procedures than those who receive standard care. * preterm neonates who receive msshh exhibit lower levels of pain and stress during invasive procedures than those who receive standard care

a quasi-experimental, pre-posttest, two group, study was carried out in nicu of in smouha, alexandria. a sample of 62 mechanically ventilated neonates were randomly assigned to two equal groups; the study group wrapped with a warm mssh during the invasive procedures while the control group received standard care of nicu. two observers independently rated the neonates' level of comfort, distress, and pain during endotracheal suctioning (ets) and heel prick using comfortneo scale. on day one of mechanical ventilation, the neonates received the same standard care of the nicu, while they wrapped with a warm mother-scented simulated hand as follow; simulated hand was scented with mothers' body odor by placing it on the mothers' bare chest or behind the neck for one hour. then, the mssh was placed under a radiant warmer for a couple of minutes to reach the mothers' unique warm touch. inside the incubator, the mechanically ventilated neonates were placed in a side-lying flexed fetal position, where they encircled with the two warm simulated human hand to contain them. where the palm of one mssh cupped the neonates' head, and the palm of the other hand cupped the lower part of body and extremities. the neonates were kept in such a position throughout the mentioned invasive procedures. neonates' physiological response, comfort, distress, and pain levels were assessed the same way as the first day.

Eligibility criteria:
inclusion criteria: * preterm * newly admitted * hemodynamic stability exclusion criteria: * receiving sedatives * low apgar score lower than three at five minutes * hypothermia * hypoglycemia * hyperglycemia * intraventricular hemorrhage grade iii\& iv * neonatal seizures

Keywords: simulated hand comfort pain distress invasive procedures preterm neonates
chronic subdural hematoma treatment with intra-arterial bevacizumab injection

Conditions: Chronic Subdural Hematoma

Summary: the goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (csdh). the main questions it aims to answer are: * is bevacizumab infusion safe in csdh patients? * is bevacizumab infusion effective in treating csdh?


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) * radiographic evidence of chronic subdural hematoma, including 1. persistence of subdural blood more than 10 days after index traumatic injury or event 2. presence of mixed density blood 3. presence of subdural membranes * can obtain informed consent and health insurance portability and accountability act (hipaa) authorization. exclusion criteria: * pregnant, breastfeeding, or unwilling to practice contraception during participation in the study. * patients with concomitant intracranial pathology other than subdural hematoma (e.g., intracranial malignancy). * patients with known hypersensitivity to bevacizumab. * patients with radiographic evidence of mass effect. * patients have focal neurological deficits attributed to subdural hematoma. * patient had craniotomy or burr hole operative procedures performed in preceding two weeks prior to onset of subdural hematoma. * secondary causes apart from trauma for the chronic subdural hematoma, such as underlying vascular abnormality or tumor. * emergent surgical evacuation is required for the patient. * non-convexity chronic subdural hematoma, as the middle meningeal artery will not supply this area. * coagulation abnormalities, including platelet count \<100,000 and/or international normalized ratio of \<1.5 despite attempts for correction. * patients with known contraindications for angiography. patients with contrast allergy will be premedicated with diphenhydramine and steroids. * patient has known active systemic infection or sepsis. * patient has contradiction to anesthetic agents used for conscious sedation/monitored anesthesia care (mac). * patient has life expectancy of less than six months due to comorbid terminal conditions. * patient has a premorbid modified rankin score (mrs) of 5 or greater. * concurrent participation in another research protocol for investigation of an experimental therapy.

Keywords: chronic subdural hematoma chronic intracranial subdural hematoma vascular endothelial growth factor bevacizumab middle meningeal artery embolization
a study to assess the safety and pharmacokinetics of ad-104-a

Conditions: Hyperlipidemias

Summary: primary endpoint of this study is to evaluate the pharmacokinetic characteristics of ad-104-a

the purpose of this study is to evaluate the pharmacokinetic characteristics of ad-104-a in healthy adult volunteers and patients with renal impairment

Eligibility criteria:
inclusion criteria: for all subjects * adults aged 19 years and older * body mass index(bmi) of 18 to 30 kg/m2 * voluntarily given written informed consent for renal impairment subjects * 30 ≤ egfr \< 90 ml/min/1.73m\^2 for healthy subjects * egfr ≥ 90 ml/min/1.73m\^2 exclusion criteria: * participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * other exclusions applied